Table 2. Key scenario analyses results for the cost analysis

Scenarios	Incremental cost	Plausibility
5-year time horizon	¶¶	This is a plausible alternative to the base case, which uses the maximum amount of available within-trial data, and benefits from a longer horizon. However, the estimate remains subject to uncertainty due to the high degree of censoring.
40-year time horizon	¶¶	This is a plausible alternative to the base case; based on median age at start of treatment, it effectively offers a lifetime horizon, which is generally the preferred approach for HTA. However, this estimate is associated with a high level of modelling uncertainty, due to censoring, extrapolation and naïve comparisons.
Weibull extrapolation (40-year time horizon)	¶¶	The Weibull distribution provides a comparable visual fit to the base case but generates more favourable estimates for both treatment arms, AWTTC considers the base case to offer a more plausible and conservative estimate.
Gilteritinib rechallenge (gilteritinib arm)	¶¶	This is a plausible alternative to the base case, which increases the incremental cost of the gilteritinib arm.

¶¶ Commercial in confidence data removed
HTA: health technology assessment